N/A N=104 Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
Tobacco Use Disorder
Primary: Product Preference — 27; 23; 24; 24 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=50 Rapid Renal Sympathetic Denervation for Resistant Hypertension
Hypertension, Resistant to Conventional Therapy
Primary: Acute Procedural Safety — 4 percentage of participants
Phase 3 N=269 Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities
Actinic Keratosis
Primary: Complete Clearance Rate — 42; 17 participants — p=0.0001
Phase 1 N=10 Bacterial Interference for Prevention of Catheter-Associated UTI: Geriatric Pilot Study
Urinary Tract Infection
Primary: Rate of UTI While Colonized With E. Coli 83972. — 8.5 UTIs per 1000 patient-days
Phase 4 N=478 Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations
Asthma
Primary: Occurrence of One or More Asthma Exacerbations (All Treatment Steps [Steps 2-5]) — 11.3; 21.0 Percent of adjusted prevalence — p=0.03
Phase 1 N=58 Persistence-Targeted Smoking Cessation
Tobacco Use Disorder
Primary: 7-day Point Prevalence Abstinence — 4; 1 participants
N/A N=1,500 Carotid Revascularization With ev3 Arterial Technology Evolution Post Approval Study
Carotid Artery Disease
Primary: Composite Rate of Death, Ipsilateral CVA, Procedure-related CVA, or Myocardial Infarction (MI) at 30 Days Post-procedure. — 99 participants
Phase 4 N=16 A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy
Chronic Diabetic Macular Edema
Primary: Changes in Best Corrected Visual Acuity From Baseline — 3.5; 0.9 Best Corrected VA Letter Score
N/A N=439 Evaluation Of New Onset Postoperative Atrial Fibrillation
Atrial Fibrillation New Onset
Primary: Primary Safety Endpoint — 3.9; 3.6 percentage of participants
N/A N=56 Core Biopsy Endo Sonography Study Evaluation of the Significance of the Pro-core® Needle
Pancreatic Neoplasm
Primary: Diagnostic Accuracy — 84 Diagnostic accuracy (%)
Phase 3 N=246 BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C
Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virologic Response at Post-treatment Week 12 (SVR12) — 50.8; 57.0; 66.7 percentage of participants
Phase 3 N=377 Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28 — -1.39; -1.02 Percentage of total hemoglobin — p=0.0072
Phase 3 N=291 Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.
Pulmonary Disease, Chronic Obstructive
Primary: Inspiratory Capacity at Rest Before Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Work Capacity — 2.502; 2.687; 2.679; 2.776 Litres — p=<0.0001
Phase 3 N=80 Clinical Trial of the Use of Intraperitoneal Local Anaesthetic
Pain, Postoperative
Primary: Reduction in Postoperative Pain — 9.2; 10; 3.3; 9.3 units on a scale
Phase 3 N=120 Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants Achieving and Maintaining Castrate Levels of Serum Testosterone (<1.735 Nmol/L) — 98.33; 82.61 Percentage of Participants